FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:651-653 August 7, 2008 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Schlenk, R. F. PubMed Citation

To the Editor: Schlenk and colleagues (May 1 issue)¹ found that patients who have cytogenetically normal acute myeloid leukemia (AML) with a genotype other than mutant NPM1 (nucleophosmin gene) without FLT3-ITDs (fms-related tyrosine kinase 3 gene internal tandem duplications) benefit from transplantation of hematopoietic stem cells from HLA-matched related donors. The authors assigned patients with an identified donor to a donor group and the other patients to a no-donor group. This method has been used in a meta-analysis involving 3103 patients.² However, the donor versus no-donor method must be restricted to HLA-typed patients with a sibling because the two . . . [Full Text of this Article]

This article has been cited by other articles:

• Schnittger, S., Kern, W., Tschulik, C., Weiss, T., Dicker, F., Falini, B., Haferlach, C., Haferlach, T. (2009). Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood 114: 2220-2231 [Abstract] [Full Text]